| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Arthritis mutilans in juvenile idiopathic arthritis
|
Miyamae, Takako
|
|
|
3 |
2 |
p. e160
|
artikel
|
| 2 |
Barriers to translational research in Sjögren's syndrome with childhood onset: challenges of recognising and diagnosing an orphan rheumatic disease
|
Ciurtin, Coziana
|
|
|
3 |
2 |
p. e138-e148
|
artikel
|
| 3 |
Changing COVID-19 outcomes in patients with rheumatic disease—are we really getting better at this?
|
Gianfrancesco, Milena A
|
|
|
3 |
2 |
p. e88-e90
|
artikel
|
| 4 |
Correction to Lancet Rheumatol 2021; 3: e71–82
|
|
|
|
3 |
2 |
p. e99
|
artikel
|
| 5 |
Efficacy matters: broadening complement inhibition in COVID-19
|
Mastellos, Dimitrios C
|
|
|
3 |
2 |
p. e95
|
artikel
|
| 6 |
Efficacy matters: broadening complement inhibition in COVID-19 – Authors' reply
|
Vlaar, Alexander P J
|
|
|
3 |
2 |
p. e95-e96
|
artikel
|
| 7 |
Genetic IL-6R variants and therapeutic inhibition of IL-6 receptor signalling in COVID-19
|
Garbers, Christoph
|
|
|
3 |
2 |
p. e96-e97
|
artikel
|
| 8 |
Genetic IL-6R variants and therapeutic inhibition of IL-6 receptor signalling in COVID-19 – Authors' reply
|
Bovijn, Jonas
|
|
|
3 |
2 |
p. e97-e98
|
artikel
|
| 9 |
Is chronic non-infectious osteomyelitis with mandibular involvement a distinct disease?
|
Murray, Grainne M
|
|
|
3 |
2 |
p. e90-e92
|
artikel
|
| 10 |
Mortality and adverse events of special interest with intravenous belimumab for adults with active, autoantibody-positive systemic lupus erythematosus (BASE): a multicentre, double-blind, randomised, placebo-controlled, phase 4 trial
|
Sheikh, Saira Z
|
|
|
3 |
2 |
p. e122-e130
|
artikel
|
| 11 |
Patient-reported wellbeing and clinical disease measures over time captured by multivariate trajectories of disease activity in individuals with juvenile idiopathic arthritis in the UK: a multicentre prospective longitudinal study
|
Shoop-Worrall, Stephanie J W
|
|
|
3 |
2 |
p. e111-e121
|
artikel
|
| 12 |
Pharmacokinetics, pharmacodynamics, and safety of subcutaneous anifrolumab in patients with systemic lupus erythematosus, active skin disease, and high type I interferon gene signature: a multicentre, randomised, double-blind, placebo-controlled, phase 2 study
|
Bruce, Ian N
|
|
|
3 |
2 |
p. e101-e110
|
artikel
|
| 13 |
Research in Brief
|
Thorley, Jennifer
|
|
|
3 |
2 |
p. e100
|
artikel
|
| 14 |
Subcutaneous anifrolumab for SLE: a new step forward?
|
Costedoat-Chalumeau, Nathalie
|
|
|
3 |
2 |
p. e84-e85
|
artikel
|
| 15 |
Systemic lupus erythematosus: diverting progress to chase rare side effects?
|
Merrill, Joan T
|
|
|
3 |
2 |
p. e87-e88
|
artikel
|
| 16 |
Temporal trends in severe COVID-19 outcomes in patients with rheumatic disease: a cohort study
|
Jorge, April
|
|
|
3 |
2 |
p. e131-e137
|
artikel
|
| 17 |
The controversial role of wellbeing assessment in juvenile idiopathic arthritis
|
Santaniello, Stefania
|
|
|
3 |
2 |
p. e85-e86
|
artikel
|
| 18 |
The multifaceted problem of pulmonary arterial hypertension in systemic sclerosis
|
Bruni, Cosimo
|
|
|
3 |
2 |
p. e149-e159
|
artikel
|
| 19 |
Too long to wait: the impact of COVID-19 on elective surgery
|
The Lancet Rheumatology,
|
|
|
3 |
2 |
p. e83
|
artikel
|
| 20 |
Variability in counselling for adrenal insufficiency in COVID-19 and beyond: a survey of rheumatology practice
|
Mehta, Puja
|
|
|
3 |
2 |
p. e92-e94
|
artikel
|
Tijdschrift beschrijving